U.S. markets close in 3 hours 1 minute

Adaptive Biotechnologies Corporation (ADPT)

NasdaqGS - NasdaqGS Real Time Price. Currency in USD
Add to watchlist
54.10-4.29 (-7.36%)
As of 12:59PM EST. Market open.
Full screen
Trade prices are not sourced from all markets
Gain actionable insight from technical analysis on financial instruments, to help optimize your trading strategies
Chart Events
Neutralpattern detected
Commodity Channel Index

Commodity Channel Index

Previous Close58.39
Open55.04
Bid54.94 x 900
Ask55.03 x 900
Day's Range53.96 - 57.85
52 Week Range15.19 - 71.25
Volume1,051,776
Avg. Volume808,180
Market Cap7.399B
Beta (5Y Monthly)N/A
PE Ratio (TTM)N/A
EPS (TTM)-0.95
Earnings DateMay 10, 2021 - May 14, 2021
Forward Dividend & YieldN/A (N/A)
Ex-Dividend DateN/A
1y Target Est62.60
Fair Value is the appropriate price for the shares of a company, based on its earnings and growth rate also interpreted as when P/E Ratio = Growth Rate. Estimated return represents the projected annual return you might expect after purchasing shares in the company and holding them over the default time horizon of 5 years, based on the EPS growth rate that we have projected.
Fair Value
XX.XX
Overvalued
Research that delivers an independent perspective, consistent methodology and actionable insight
Related Research
View more
  • Benzinga

    Adaptive Biotechnologies: Q4 Earnings Insights

    Shares of Adaptive Biotechnologies (NASDAQ:ADPT) fell in after-market trading after the company reported Q4 results. Quarterly Results Earnings per share decreased 94.12% year over year to ($0.33), which missed the estimate of ($0.29). Revenue of $30,185,000 higher by 24.69% year over year, which beat the estimate of $26,900,000. Guidance Adaptive Biotechnologies hasn't issued any earnings guidance for the time being. Revenue guidance hasn't been issued by the company for now. How To Listen To The Conference Call Date: Feb 24, 2021 View more earnings on ADPT Time: 04:30 PM ET Webcast URL: https://edge.media-server.com/mmc/p/y7tyzac4 Recent Stock Performance Company's 52-week high was at $71.25 52-week low: $15.19 Price action over last quarter: Up 12.44% Company Description Adaptive Biotechnologies Corp is a commercial-stage company advancing the field of immune-driven medicine by harnessing the inherent biology of the adaptive immune system to transform the diagnosis and treatment of disease. Its clinical diagnostic product, clonoSEQ, is test authorized by the FDA for the detection and monitoring of minimal residual disease in patients with select blood cancers. See more from BenzingaClick here for options trades from BenzingaRecap: Staar Surgical Q4 EarningsGreif: Q1 Earnings Insights© 2021 Benzinga.com. Benzinga does not provide investment advice. All rights reserved.

  • Adaptive Biotechnologies Reports Fourth Quarter and Full Year 2020 Financial Results
    GlobeNewswire

    Adaptive Biotechnologies Reports Fourth Quarter and Full Year 2020 Financial Results

    SEATTLE, Feb. 24, 2021 (GLOBE NEWSWIRE) -- Adaptive Biotechnologies Corporation ("Adaptive Biotechnologies") (Nasdaq: ADPT), a commercial stage biotechnology company that aims to translate the genetics of the adaptive immune system into clinical products to diagnose and treat disease, today reported financial results for the fourth quarter and full year ended December 31, 2020. "Adaptive's launch of T-Detect COVID marks a pivotal moment in the diagnostic testing paradigm. We have now proven that it is possible to read how T cells detect disease in the blood and we are on a fast path to develop this product for many other indications," said Chad Robins, chief executive officer and co-founder of Adaptive Biotechnologies. "As we move into 2021, we are poised to execute on several key catalysts across all business areas that will accelerate our vision to power the age of immune medicine." Recent Highlights Revenues of $30.2 million for the fourth quarter and $98.4 million for the full year of 2020, representing a 25% increase and 16% increase, respectively, over the corresponding periods in 2019.Clinical sequencing volume increased 41% to 4,539 clinical tests delivered in the fourth quarter of 2020, compared to the fourth quarter 2019 and ended the year with 15,216 clinical tests delivered, up 50% versus 2019.Launched T-Detect™ COVID, first clinical T-cell based test for patients to confirm recent or prior COVID-19 infection. In final review by the U.S. Food and Drug Administration (FDA) for Emergency Use Authorization (EUA).Extended collaboration agreement with Labcorp to enable broader access to our growing portfolio of immune-driven clinical diagnostic and research products.Submitted a 510(k) application to the FDA for the use of clonoSEQ in blood for B-cell acute lymphoblastic leukemia (ALL) patients. Fourth Quarter 2020 Financial Results Revenue was $30.2 million for the quarter ended December 31, 2020, representing a 25% increase from the fourth quarter in the prior year. Sequencing revenue was $12.7 million for the quarter, representing an 8% decrease from the fourth quarter in the prior year. Development revenue was $17.5 million for the quarter, representing a 69% increase from the fourth quarter in the prior year. Operating expenses were $74.4 million for the fourth quarter of 2020, compared to $48.4 million in the fourth quarter of the prior year, representing an increase of 54%. Net loss was $44.6 million for the fourth quarter of 2020, compared to $20.6 million for the same period in 2019. Adjusted EBITDA (non-GAAP) was a loss of $34.6 million for the fourth quarter of 2020, compared to a loss of $18.7 million for the fourth quarter of the prior year. Full Year 2020 Financial Results Revenue was $98.4 million for the year ended December 31, 2020, representing a 16% increase from the prior year. Sequencing revenue was $41.4 million in 2020, representing a 5% decrease from 2019. Development revenue was $56.9 million in 2020, representing a 37% increase from the prior year. Operating expenses for 2020 were $251.2 million, compared to $163.5 million for 2019, representing an increase of 54%. Net loss was $146.2 million in 2020, compared to $68.6 million in 2019. Adjusted EBITDA (non-GAAP) was a loss of $119.6 million for 2020, compared to a loss of $57.5 million in the prior year. Cash, cash equivalents and marketable securities was $806.8 million as of December 31, 2020. 2021 Financial Guidance Management will provide the 2021 outlook during the conference call scheduled to discuss the 2020 financial results. Webcast and Conference Call Information Adaptive Biotechnologies will host a conference call to discuss its fourth quarter and full year 2020 financial results after market close on Wednesday, February 24, 2021 at 4:30 PM Eastern Time. The conference call can be accessed at http://investors.adaptivebiotech.com. The webcast will be archived and available for replay at least 90 days after the event. About Adaptive Biotechnologies Adaptive Biotechnologies ("we" or "our") is a commercial-stage biotechnology company focused on harnessing the inherent biology of the adaptive immune system to transform the diagnosis and treatment of disease. We believe the adaptive immune system is nature's most finely tuned diagnostic and therapeutic for most diseases, but the inability to decode it has prevented the medical community from fully leveraging its capabilities. Our proprietary immune medicine platform reveals and translates the massive genetics of the adaptive immune system with scale, precision and speed to develop products in life sciences research, clinical diagnostics and drug discovery. We have three commercial products and a robust clinical pipeline to diagnose, monitor and enable the treatment of diseases such as cancer, autoimmune conditions and infectious diseases. Our goal is to develop and commercialize immune-driven clinical products tailored to each individual patient. Forward-Looking Statements This press release contains forward-looking statements that are based on management's beliefs and assumptions and on information currently available to management. All statements contained in this release other than statements of historical fact are forward-looking statements, including statements regarding our ability to develop, commercialize and achieve market acceptance of our current and planned products and services, our research and development efforts and other matters regarding our business strategies, use of capital, results of operations and financial position and plans and objectives for future operations. In some cases, you can identify forward-looking statements by the words "may," "will," "could," "would," "should," "expect," "intend," "plan," "anticipate," "believe," "estimate," "predict," "project," "potential," "continue," "ongoing" or the negative of these terms or other comparable terminology, although not all forward-looking statements contain these words. These statements involve risks, uncertainties and other factors that may cause actual results, levels of activity, performance or achievements to be materially different from the information expressed or implied by these forward-looking statements. These risks, uncertainties and other factors are described under "Risk Factors," "Management's Discussion and Analysis of Financial Condition and Results of Operations" and elsewhere in the documents we file with the Securities and Exchange Commission from time to time. We caution you that forward-looking statements are based on a combination of facts and factors currently known by us and our projections of the future, about which we cannot be certain. As a result, the forward-looking statements may not prove to be accurate. The forward-looking statements in this press release represent our views as of the date hereof. We undertake no obligation to update any forward-looking statements for any reason, except as required by law. Use of Non-GAAP Financial Measure To supplement our balance sheets and statements of operations, which are prepared in conformity with generally accepted accounting principles in the United States of America ("GAAP"), this press release also includes references to Adjusted EBITDA, which is a non-GAAP financial measure that we define as net loss adjusted for interest and other income, net, income tax (expense) benefit, depreciation and amortization and share-based compensation expenses. We have provided a reconciliation of net loss, the most directly comparable GAAP financial measure, to Adjusted EBITDA at the end of this press release. Management uses Adjusted EBITDA to evaluate the financial performance of our business and the effectiveness of our business strategies. We present Adjusted EBITDA because we believe it is frequently used by analysts, investors and other interested parties to evaluate companies in our industry and it facilitates comparisons on a consistent basis across reporting periods. Further, we believe it is helpful in highlighting trends in our operating results because it excludes items that are not indicative of our core operating performance. Adjusted EBITDA has limitations as an analytical tool and you should not consider it in isolation, or as a substitute for analysis of our results as reported under GAAP. We may in the future incur expenses similar to the adjustments in the presentation of Adjusted EBITDA. In particular, we expect to incur meaningful share-based compensation expense in the future. Other limitations include that Adjusted EBITDA does not reflect: all expenditures or future requirements for capital expenditures or contractual commitments;changes in our working capital needs;income tax (expense) benefit, which may be a necessary element of our costs and ability to operate;the costs of replacing the assets being depreciated and amortized, which will often have to be replaced in the future;the non-cash component of employee compensation expense; andthe impact of earnings or charges resulting from matters we consider not to be reflective, on a recurring basis, of our ongoing operations. In addition, Adjusted EBITDA may not be comparable to similarly titled measures used by other companies in our industry or across different industries. ADAPTIVE MEDIABeth Keshishian917-912-7195media@adaptivebiotech.com ADAPTIVE INVESTORSKarina Calzadilla, Vice President, Investor Relations201-396-1687Carrie Mendivil, Gilmartin Groupinvestors@adaptivebiotech.com Adaptive BiotechnologiesStatements of Operations(in thousands, except share and per share amounts)(unaudited) Three Months Ended December 31, Year Ended December 31, 2020 2019 2020 2019 Revenue Sequencing revenue $12,709 $13,888 $41,439 $43,519 Development revenue 17,476 10,321 56,943 41,552 Total revenue 30,185 24,209 98,382 85,071 Operating expenses Cost of revenue 6,222 5,951 22,530 22,274 Research and development 35,831 21,189 116,072 70,705 Sales and marketing 18,545 12,640 61,358 38,453 General and administrative 13,398 8,189 49,536 30,332 Amortization of intangible assets 428 428 1,703 1,698 Total operating expenses 74,424 48,397 251,199 163,462 Loss from operations (44,239) (24,188) (152,817) (78,391)Interest and other income, net 785 3,577 6,590 9,785 Income tax expense (1,116) — — — Net loss (44,570) (20,611) (146,227) (68,606)Fair value adjustment to Series E-1 convertible preferred stock options — — — (964)Net loss attributable to common shareholders $(44,570) $(20,611) $(146,227) $(69,570)Net loss per share attributable to common shareholders, basic and diluted $(0.33) $(0.17) $(1.11) $(1.01)Weighted-average shares used in computing net loss per share attributable to common shareholders, basic and diluted 136,954,148 124,397,150 131,216,468 69,165,315 Adaptive BiotechnologiesBalance Sheets(in thousands, except share and per share amounts)(unaudited) December 31, 2020 2019 Assets Current assets Cash and cash equivalents $123,436 $96,576 Short-term marketable securities (amortized cost of $564,036 and $479,791, respectively) 564,833 480,290 Accounts receivable, net 10,047 12,676 Inventory 14,063 9,069 Prepaid expenses and other current assets 14,535 14,079 Total current assets 726,914 612,690 Long-term assets Property and equipment, net 39,692 60,355 Operating lease right-of-use assets 99,350 — Long-term marketable securities (amortized cost of $118,429 and $105,263, respectively) 118,525 105,435 Restricted cash 2,138 2,138 Intangible assets, net 10,225 11,928 Goodwill 118,972 118,972 Other assets 598 784 Total assets $1,116,414 $912,302 Liabilities and shareholders' equity Current liabilities Accounts payable $3,237 $4,453 Accrued liabilities 13,162 4,371 Accrued compensation and benefits 11,950 8,124 Current portion of deferred rent — 371 Current portion of operating lease liabilities 3,529 — Current portion of deferred revenue 73,319 60,994 Total current liabilities 105,197 78,313 Long-term liabilities Deferred rent liability, less current portion — 6,918 Operating lease liabilities, less current portion 104,333 — Financing obligation — 36,607 Deferred revenue, less current portion 163,618 219,332 Other long-term liabilities — 93 Total liabilities 373,148 341,263 Commitments and contingencies Shareholders' equity Preferred stock: $0.0001 par value, 10,000,000 shares authorized at December 31, 2020 and 2019; no shares issued and outstanding at December 31, 2020 and 2019 — — Common stock: $0.0001 par value, 340,000,000 shares authorized at December 31, 2020 and 2019; 137,646,896 and 125,238,142 shares issued and outstanding at December 31, 2020 and 2019, respectively 14 12 Additional paid-in capital 1,253,971 935,834 Accumulated other comprehensive gain 893 671 Accumulated deficit (511,612) (365,478)Total shareholders' equity 743,266 571,039 Total liabilities and shareholders' equity $1,116,414 $912,302 Adjusted EBITDAThe following table sets forth a reconciliation between our Adjusted EBITDA and our net loss, the most directly comparable GAAP financial measure, for each of the periods presented (in thousands, unaudited): Three Months Ended December 31, Year Ended December 31, 2020 2019 2020 2019 Net loss $(44,570) $(20,611) $(146,227) $(68,606)Interest and other income, net (785) (3,577) (6,590) (9,785)Income tax expense 1,116 — — — Depreciation and amortization expense 2,352 2,075 8,472 7,791 Share-based compensation expense 7,243 3,411 24,761 13,124 Adjusted EBITDA $(34,644) $(18,702) $(119,584) $(57,476)